drugset / Trial / NCT00544115

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

NCT00544115

Phase 2 Active not recruiting 260 enrolled City of Hope Medical Center National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving tacrolimus, methotrexate, cyclosporine, mycophenolate mofetil, and sirolimus before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well donor peripheral stem cell transplant works in treating patients with advanced hematologic cancer or other disorders.

Timeline

Start
2001-10-16
Primary completion
2007-03-13
Completion
2027-03-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Busulfan Small molecule Intravenous
Comparator Cyclophosphamide Other / unclassified Intravenous
Comparator Cyclosporine Peptide Intravenous
Comparator Etoposide Small molecule Intravenous
Comparator Fludarabine Small molecule Intravenous
Comparator Melphalan Small molecule Intravenous
Comparator Methotrexate Small molecule Intravenous
Comparator Mycophenolate Mofetil Small molecule Intravenous
Comparator Sirolimus Small molecule Oral
Comparator Tacrolimus Small molecule Intravenous